Loading...
•
Mar 31
cbdMD Q2 2025 Earnings Report
Delivered year-over-year revenue growth and narrowed operating loss.
Key Takeaways
cbdMD reported $4.75 million in revenue in Q2 2025, up 8.6% YoY. Gross margin improved to 62%, and operating loss narrowed significantly. The company completed a capital restructuring and maintained strong direct-to-consumer sales while gaining momentum in new product lines like Herbal Oasis.
Revenue rose to $4,749,426, up 8.6% from Q2 2024.
Gross margin increased to 62% from 59% in Q2 2024.
Operating loss decreased to $485,816, down from $1.55 million.
Cash and cash equivalents stood at $1,765,234 as of March 31, 2025.
cbdMD
cbdMD
Forward Guidance
cbdMD aims to sustain revenue growth and operational efficiency, supported by product innovation and a clean capital structure following the Series A conversion.
Positive Outlook
- Herbal Oasis brand expanded into three new states
- All four Herbal Oasis flavors won medals at High Spirits Awards
- Series A Preferred conversion eliminated $6.7M in dividends
- Adjusted EBITDA loss reduced to $197,986 from $678,189
- Capital structure reset positions company for future compliance and growth
Challenges Ahead
- Net loss attributable to shareholders was $1.48M
- Free cash flow was negative at $507,426
- Cash balance declined to $1.76M from $2.45M
- Working capital deficit stood at $3.7M including preferred dividends
- DTC sales as a percentage of total sales declined from 83% to 77%